Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors

被引：39

作者：

Sequist, Lecia V. ^{[1
]}

Cassier, Phillippe ^{[2
]}

Varga, Andrea ^{[3
]}

Tabernero, Josep ^{[4
]}

Schellens, Jan H. ^{[5
]}

Delord, Jean-Pierre ^{[6
]}

LoRusso, Patricia ^{[7
]}

Camidge, D. Ross ^{[8
]}

Hidalgo Medina, Manuel ^{[9
]}

Schuler, Martin ^{[10
]}

Campone, Mario ^{[11
]}

Tian, G. Gary ^{[12
]}

Wong, Steven ^{[13
]}

Corral, Jesus ^{[14
]}

Isaacs, Randi ^{[15
]}

Sen, Suman K. ^{[16
]}

Porta, Diana Graus ^{[17
]}

Kulkarni, Swarupa G. ^{[16
]}

Lefebvre, Caroline ^{[18
]}

Wolf, Juergen ^{[19
]}

机构：

[1] Massachusetts Gen Hosp, Boston, MA 02114 USA

[2] Ctr Leon Berard, F-69373 Lyon, France

[3] Inst Gustave Roussy, Villejuif, France

[4] Vall dHebron Univ Hosp, Barcelona, Spain

[5] Netherlands Canc Inst, Amsterdam, Netherlands

[6] Inst Claudius Regaud, Toulouse, France

[7] Karmanos Canc Inst, Detroit, MI USA

[8] Univ Colorado, Aurora, CO USA

[9] Spanish Natl Canc Res Ctr CNIO, Madrid, Spain

[10] Univ Duisburg Essen, West German Canc Ctr, Essen, Germany

[11] Ctr Rene Gauducheau, F-44035 Nantes, France

[12] West Clin, Memphis, TN USA

[13] UCLA Med Ctr, Los Angeles, CA USA

[14] Univ Hosp Virgen del Rocio, Seville, Spain

[15] Novartis OTM, E Hanover, NJ USA

[16] Novartis Pharmaceut, E Hanover, NJ USA

[17] NIBR Oncol, Basel, Switzerland

[18] Novartis OTM, Basel, Switzerland

[19] Univ Hosp Cologne, Cologne, Germany

来源：

CANCER RESEARCH | 2014年 / 74卷 / 19期

关键词：

D O I：

10.1158/1538-7445.AM2014-CT326

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT326

引用

页数：2

共 50 条

[1] A phase I dose escalation study of NVP-BGJ398, a selective pan FGFR inhibitor in genetically preselected advanced solid tumors
Wolf, Jurgen
LoRusso, Patricia M.
Camidge, Ross D.
Manuel Perez, Jose
Tabernero, Josep
Hidalgo, Manuel
Schuler, Martin
Tian, Gary G.
Soria, Jean Charles
Delord, Jean Pierre
Campone, Mario
Bachelot, Thomas
van der Noll, Ruud
Ringeisen, Francois P.
Nogova, Lucia
Sequist, Lecia V.
Schellens, Jan H. M.
CANCER RESEARCH, 2012, 72
[2] A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor
Kelly, Ciara M.
Shoushtari, Alexander N.
Qin, Li-Xuan
D'Angelo, Sandra P.
Dickson, Mark A.
Gounder, Mrinal M.
Keohan, Mary Louise
Mcfadyen, Chloe
Sjoberg, Ana
Singer, Samuel
DeMatteo, Ronald P.
Hwang, Sinchun
Heinemann, M. H.
Francis, Jasmine H.
Antonescu, Cristina R.
Chi, Ping
Tap, William D.
INVESTIGATIONAL NEW DRUGS, 2019, 37 (02) : 282 - 290
[3] A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor
Ciara M. Kelly
Alexander N. Shoushtari
Li-Xuan Qin
Sandra P. D’Angelo
Mark A. Dickson
Mrinal M. Gounder
Mary Louise Keohan
Chloe Mcfadyen
Ana Sjoberg
Samuel Singer
Ronald P. DeMatteo
Sinchun Hwang
M. H. Heinemann
Jasmine H. Francis
Cristina R. Antonescu
Ping Chi
William D. Tap
Investigational New Drugs, 2019, 37 : 282 - 290
[4] BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression
Kim, Se Hyun
Ryu, Haram
Ock, Chan-Young
Suh, Koung Jin
Lee, Ji Yun
Kim, Ji-Won
Lee, Jeong-Ok
Kim, Jin Won
Kim, Yu Jung
Lee, Keun-Wook
Bang, Soo-Mee
Kim, Jee Hyun
Lee, Jong Seok
Ahn, Joong Bae
Kim, Kui-Jin
Rha, Sun Young
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (10)
[5] BGJ398, a pan-FGFR inhibitor, overcomes paclitaxel resistance in urothelial carcinoma with FGFR1 overexpression
Ryu, Haram
Kim, Se Hyun
Ock, Chan-Young
Suh, Koung Jin
Lee, Ji Yun
Kim, Ji-Won
Kim, Jin Won
Lee, Jeong-Ok
Kim, Yu Jung
Lee, Keun-Wook
Bang, Soo-Mee
Kim, Jee Hyun
Lee, Jong Seok
Ahn, Joong Bae
Kim, Kui-Jin
Rha, Sun Young
CANCER RESEARCH, 2019, 79 (13)
[6] THE FGFR INHIBITOR BGJ398 HAS ACTIVITY IN TUMORS WITH FGFR ALTERATIONS
不详
CANCER DISCOVERY, 2017, 7 (01) : 12 - 12
[7] Patient stratification strategies for NVP-BGJ398, a selective pan-FGFR inhibitor in phase I clinical trials
Porta, Diana Graus
Guagnano, Vito
Stamm, Christelle
Woehrle, Simon
Kauffmann, Audrey
Yao, Yao
Brummendorf, Thomas
Bordas, Vincent
Le Douget, Mickael
Zhang, Yun
Chen, Zhi
Ito, Moriko
Li, Fang
Monahan, John
Gaither, Alex
Borawski, Jason
Wilson, Christopher J.
Venkatesan, Kavitha
Hofmann, Francesco
Sellers, William
CANCER RESEARCH, 2012, 72
[8] Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions
Javle, M.
Kelley, R. K.
Roychowdhury, S.
Weiss, K. H.
Abou-Alfa, G. K.
Macarulla, T.
Sadeghi, S.
Waldschmidt, D.
Zhu, A. X.
Goyal, L.
Borad, M.
Yong, W. P.
Borbath, I.
El-Khoueiry, A.
Philip, P.
Moran, S.
Ye, Y.
Ising, M.
Lewis, N.
Bekaii-Saab, T.
ANNALS OF ONCOLOGY, 2018, 29 : 720 - 720
[9] FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor
Guagnano, Vito
Kauffmann, Audrey
Woehrle, Simon
Stamm, Christelle
Ito, Moriko
Barys, Louise
Pornon, Astrid
Yao, Yao
Li, Fang
Zhang, Yun
Chen, Zhi
Wilson, Christopher J.
Bordas, Vincent
Le Douget, Mickael
Gaither, L. Alex
Borawski, Jason
Monahan, John E.
Venkatesan, Kavitha
Bruemmendorf, Thomas
Thomas, David M.
Garcia-Echeverria, Carlos
Hofmann, Francesco
Sellers, William R.
Graus-Porta, Diana
CANCER DISCOVERY, 2012, 2 (12) : 1118 - 1133
[10] Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Javle, Milind
Lowery, Maeve
Shroff, Rachna T.
Weiss, Karl Heinz
Springfeld, Christoph
Borad, Mitesh J.
Ramanathan, Ramesh K.
Goyal, Lipika
Sadeghi, Saeed
Macarulla, Teresa
El-Khoueiry, Anthony
Kelley, Robin Kate
Borbath, Ivan
Choo, Su Pin
Oh, Do-Youn
Philip, Philip A.
Chen, Li-Tzong
Reungwetwattana, Thanyanan
Van Cutsem, Eric
Yeh, Kun-Huei
Ciombor, Kristen
Finn, Richard S.
Patel, Anuradha
Sen, Suman
Porter, Dale
Isaacs, Randi
Zhu, Andrew X.
Abou-Alfa, Ghassan K.
Bekaii-Saab, Tanios
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (03) : 276 - +

← 1 2 3 4 5 →